BEAM Reports $1.2B Cash, $0.00 EPS, +$1.2B Runway to 2029, BEAM-302 60mg Optimal Dose, BEACON NEJM Publication, BLA 2026, TIME100 Honoree
Beam Therapeutics Inc. Common Stock · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · Now $31.14
-15% in 7d after detection
Post-detection moves
1h
—
1d
+2.7%
3d
+0.3%
7d
-15%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS